BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced the U.S. availability of BREXAFEMME® (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) for a biodegradable implant including naltrexone.

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors

Q BioMed Inc. is pleased to provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome (ARDS), a condition caused by viral infections in the lungs including COVID-19.

Akari Therapeutics, Plc today announced its financial results for the second quarter of 2021, as well as recent clinical progress.

PathAI, a global provider of artificial intelligence-powered (AI-powered) technology for pathology, and Summit Clinical Research, an integrated research organization that advises sponsors on Non-Alcoholic Steatohepatitis (NASH) clinical optimization, today announced a partnership offering an integrated solution to NASH drug developers in support of their clinical development programs.

Hexagon Bio today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.

Muno-Vax has created a suite of products that utilize a potent immuno-modulator to maximize the effectiveness of the immune system.

IsoPlexis, a leader in functional single-cell proteomics, today announced the appointment of Dr. Jason Myers to its Board of Directors.

OncoNano Medicine, Inc. today announced a multi-year collaboration with The University of Texas Southwestern Medical Center (UTSW) to discover and conduct translational research of novel cancer therapeutics that leverage OncoNano’s core nanotechnology platform.